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Abstract
Objectives Volume of necrosis in Wilms tumour is informative of chemotherapy response. Contrast-enhanced T1-weighted MRI
(T1w) provides a measure of necrosis using gadolinium. This study aimed to develop a non-invasive method of identifying non-
enhancing (necrotic) tissue in Wilms tumour.
Methods In this single centre, retrospective study, post-chemotherapy MRI data from 34 Wilms tumour patients were reviewed
(March 2012–March 2017). Cases with multiple b value diffusion-weighted imaging (DWI) and T1w imaging pre- and post-
gadoliniumwere included. Fractional T1 enhancement maps were generated from the gadolinium T1w data.Multiple linear regression
determined whether fitted parameters from a mono-exponential model (ADC) and bi-exponential model (IVIM – intravoxel inco-
herent motion) (D,D*, f) could predict fractional T1 enhancement inWilms tumours, using normalised pre-gadoliniumT1w (T1wnorm)
signal as an additional predictor. Measured and predicted fractional enhancement values were compared using the Bland-Altman plot.
An optimum threshold for separating necrotic and viable tissue using fractional T1 enhancement was established using ROC.
Results ADC and D (diffusion coefficient) provided the strongest predictors of fractional T1 enhancement in tumour tissue
(p < 0.001). Using the ADC-T1wnorm model (adjusted R
2 = 0.4), little bias (mean difference = − 0.093, 95% confidence interval =
[− 0.52, 0.34]) was shown between predicted and measured values of fractional enhancement and analysed via the Bland-Altman
plot. The optimal threshold for differentiating viable and necrotic tissue was 33% fractional T1 enhancement (based on measured
values, AUC= 0.93; sensitivity = 85%; specificity = 90%).
Conclusions Combining ADC and T1w imaging predicts enhancement in Wilms tumours and reliably identifies and measures
necrotic tissue without gadolinium.
Key Points
• Alternative method to identify necrotic tissue in Wilms tumour without using contrast agents but rather using diffusion and
T1weighted MRI.
• A method is presented to visualise and quantify necrotic tissue in Wilms tumour without contrast.
• The proposed method has the potential to reduce costs and burden to Wilms tumour patients who undergo longitudinal follow-
up imaging as contrast agents are not used.
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Wilms tumour is the most common type of paediatric renal
tumour, accounting for approximately 90% of all kidney tu-
mours [1]. In Europe, patients are treated under the SIOP
approach (Société Internationale d′Oncologie Pédiatrique), in
which they undergo pre-operative chemotherapy to reduce
tumour size prior to surgery [2].
Necrosis withinWilms tumour post-chemotherapy is infor-
mative of treatment response, particularly when tumour size
remains stable. It has been suggested that patients with 100%
necrosis post-chemotherapy, when assessed via histological
analysis, are associated with relapse-free survival at 5-year
follow-up [3]. Thus, quantifying the degree of necrosis in
Wilms tumour tissue is beneficial. In the body, MRI can iden-
tify necrotic tissue via administration of gadolinium-based
contrast agents and T1-weighted imaging (T1w), where absent
or decreased enhancement may represent necrosis. However,
gadolinium requires venous access and raises examination
costs. In addition, recent reports have described gadolinium
retention in neural and body tissue regardless of renal func-
tion; however, currently, there are no known sequelae related
to this [4]. While, gadolinium is still frequently administered
and has many additional uses, an alternative approach to iden-
tify and quantify necrosis would be beneficial.
The apparent diffusion coefficient (ADC), derived from
diffusion-weighted imaging (DWI), has been shown to be
related to cell density; low ADC values correlate with high
cell counts in a range of paediatric body tumours [5]. ADC
values have been shown to increase following chemotherapy
in abdominal tumours [6] and specifically in Wilms tumour
[7]. Thus, areas of necrosis in Wilms tumour could potentially
be identified as regions with low cellular density, which can
result in higher ADC values. However, lower ADC values do
not necessarily indicate viable tissue; necrosis by coagulation
results in low ADC values which mimics high cellular density
tissue [8]. However, hyper-intense regions on pre-gadolinium
T1w images can indicate areas of coagulated blood; thus, we
hypothesise combining ADC and pre-gadolinium T1w may
enable necrosis in Wilms tumour to be identified and quanti-
fied, without the need for exogenous contrast agents.
Furthermore, research has suggested that alternative non-
Gaussian diffusion models for DWI, such as intravoxel inco-
herent motion (IVIM) [9], provide a more accurate description
of the diffusionMR signal and provide additional information
about tissue-microstructure compared to the standard mono-
exponential model [10]. IVIM could be particularly beneficial
in assessing necrosis, as it accounts for the influence of blood
flow on the DWI signal [11], which should be absent in ne-
crotic tissue.
In this study, we hypothesise that the combination of T1w
imaging and DWI could estimate the degree of necrosis in
Wilms tumour, as opposed to the more traditional method of
using gadolinium. We also investigate whether diffusion pa-
rameters from IVIM could improve this estimation.
Additionally, we aim to establish an upper threshold of en-
hancement, based on typical values found in necrotic tumour
tissue, as defined by manual delineation of necrotic tumour
regions on post-gadolinium T1 images by two radiologists.
Tissue which shows enhancement below this threshold (using
either measured or predicted enhancement data) can be clas-
sified as necrotic, allowing the quantification of the volume
fraction of necrotic tissue in future Wilms tumour studies.
Materials and methods
Study population
Institutional ethical approval was granted and waived the need
for consent for this single centre study. A 5-year retrospective
review (March 2012–2017) of the radiology imaging system
(RIS) was performed for all MRI abdominal studies in chil-
dren with proven histological diagnosis of Wilms tumour at
our institution. Inclusion criteria were children who had com-
pleted a full 6-week course of chemotherapy, with MRI se-
quences that included both DWI and T1w sequences (pre- and
post-gadolinium contrast). Cases where the post-
chemotherapy size of the tumour did not cover more than
two axial slices on diffusion imaging were excluded. Eight
patients from our cohort have previously been reported in
[7] although this did not focus on necrosis detection.
MRI
All imaging was performed on a 1.5 T Siemens Magnetom
Avanto scanner equipped with 40 mT/m gradients. Depending
on patient size, one or two body matrix coils were used to obtain
full coverage (6 element design, Siemens). All patients
underwent DWI followed by T1w imaging pre- and post-gado-
linium. TheDWI protocolwas as follows: 7 or 8 b values in three
orthogonal directions (0, 50, 100, 250, 500, 750, 1000 s/mm2
(8 Wilms tumours) or 0, 50, 100, 150, 200, 250, 500, 1000 s/mm2
(29 Wilms tumour)); slice thickness, 6 mm; TR/TE,
2600 ms/89 ms; and field of view, 350 mm. Axial T1-weighted
imaging was acquired both before and after intravenous
administration of gadolinium-based contrast using identical
protocols for the pre- and post-gadolinium acquisitions. The
full imaging parameters of all clinical sequences used can be
found in [6].
Contrast agents
All patients received Dotarem 0.5 mmol/ml (manufactured by
Guerbet), dosage 0.2 ml per kg body-weight. The post-
contrast T1 sequence was started 2 to 4 min after injection of
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contrast agent. Hyoscine butylbromide (Buscopan) 20 mg/ml
(manufactured by Sanofi) was also administered prior to all
sequences to prevent peristalsis, dosage 0.02 ml per kg body-
weight; however, maximum dosage was based on patient age,
1 month–4 years = 0.25 ml maximum and 4 years–12 years =
0.5 ml maximum.
Post-processing
Data processing and analysis were performed using in-house
routines written in Matlab R2015b (MathWorks Inc., Natick).
All registrations were performed using NiftyReg [12] pack-
ages using affine transformations, and regions of interest
(ROIs) were generated using Mango Software (Research
Imaging Institute, UTHSCSA).
Tumour ROIs were independently drawn by two radiolo-
gists specialising in paediatric radiology (S.S, 4 years paedi-
atric radiology; M.V, 2 years paediatric radiology). ROIs were
drawn around the perimeters of each Wilms tumour on b = 0
(non-diffusion-weighted) images on each axial slice, using all
clinically acquired images for guidance. The overlapping
areas (between the two radiologists) were defined as the final
Wilms tumour ROIs. ROIs which displayed substantial visual
mismatch between the two radiologists were reviewed until
consensus was achieved. To compare similarity of size be-
tween the independently defined ROIs, the intraclass correla-
tion coefficient (ICC) was calculated.
Data from each patient was processed twice by two differ-
ent models of diffusion. A mono-exponential fit [Eq. 1] gen-
erated ADC; fitting was performed on a voxel-by-voxel basis
across all b values. A bi-exponential model (IVIM9) [Eq. 2]
generated the parameters D (thermally driven, ‘slow’ diffu-
sion), D* (flow-driven, ‘fast’ diffusion), and f (volume frac-
tion associated with ‘fast’ diffusion). In each instance, S(b) is
the signal at a given b value, and S0 is the signal with no
diffusion weighting:
S bð Þ ¼ S0e−b:ADC ð1Þ
S bð Þ ¼ S0 1 − fð Þe−b:D þ f e−b: D þ D*ð Þ ð2Þ
The fitted parameters (D, D*, and f) were calculated in a
stepwise fashion. Firstly, a linear fit of ln(S/S0) against b was
calculated at high b values (200–1000 s/mm2) to determine
the value ofD. Following this,D* and fwere fit simultaneous-
ly using the full b value range (with a fixed D) to improve the
stability of the model fitting process.D* had no constraints on
upper boundaries, and fwas constrained between 0 and 1. This
fitting was performed using the Levenberg-Marquardt nonlin-
ear least squares algorithm. All parameter maps were then
smoothed with a 2-mm Gaussian kernel.
Fractional enhancement maps were generated from T1w
scans. Post-gadolinium T1w images (post-Gd T1w) were
registered to pre-gadolinium T1w images (pre-Gd T1w). All
T1w scans were smoothed with a 2-mm Gaussian kernel to
counteract registration errors. Voxel-wise fractional enhance-
ment maps were calculated, using fractional enhancement =
((post-Gd T1w – pre-Gd T1w)/(pre-Gd T1w)). For example, a
fractional enhancement of 0.50 indicates a 50% increase in
signal intensity on the T1w image following gadolinium ad-
ministration. Fractional enhancement maps were co-registered
to DWI space. Additionally, pre-Gd T1w images were normal-
ised to mean pre-Gd T1w signal intensity in a reference tissue
in each patient, to produce quantitative, normalised pre-Gd
T1w images (T1wnorm). This was achieved by dividing each
pre-Gd T1w image by the mean signal intensity in an ROI
placed in normal-appearing erector spinae muscles for each
patient. These normalised pre-Gd T1w images were also reg-
istered to the DWI scans.
Analysis and statistics
Wilms tumour ROIs were placed on co-registered fractional
enhancement, diffusion, and T1wnorm maps. Mean values
were calculated for each parameter in every Wilms tumour.
The diffusion parameters included ADC and the fitted IVIM
parameters (D, D*, and f). Additionally, the parameter f × D*
was investigated. Multiple linear regression was used to cal-
culate the relationship between mean fractional enhancement
(dependent variable) and a combination of the mean of a sin-
gle diffusion parameter and mean T1wnorm (predictor vari-
ables). Statistically significant regression coefficients were de-
fined as having a p value < 0.05. Models were then compared
based on adjusted R2 values.
Using the selected regression model, voxel-wise-predicted
enhancement maps were generated for each Wilms tumour.
Using the Bland-Altman plot, whole tumour values of predict-
ed and measured fractional enhancement were compared, to
determine the similarity (confidence intervals) and level of
bias (mean difference) between the two techniques.
We also determined an upper threshold for enhancement in
necrotic tissue, which would allow tumours to be separated
into viable and necrotic components. Regions within each
tumour which confidently represented necrosis were indepen-
dently delineated by the two radiologists, using all clinically
acquired MR sequences for guidance. The overlapping areas
between the radiologists were defined as the final necrotic
ROIs. These were used as the ‘gold-standard’ to represent
the necrotic part of each tumour. The remainder of the
Wilms tumour was defined as the viable ROI. Both viable
and necrotic ROIs were registered onto corresponding mea-
sured fractional enhancement maps. The fractional enhance-
ment value of every necrotic and viable voxel was pooled
across the cohort. ROC analysis was used to define a fraction-
al enhancement threshold which best separated viable and
necrotic tissue based on AUC (area under curve). Tissue
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within a Wilms tumour with enhancement below this thresh-
old would be classified as necrotic, and tissue with enhance-




A total of 37 Wilms tumours from 34 patients were included
as the final cohort. The median age of patients at the time of
their MRI scans was 2.6 years (mean, 3.3 years; SD, 2.6;
minimum, 0.4 years; maximum, 11.0 years). Patient inclusion
and exclusion metrics are shown in Fig. 1.
Post-processing
After initial delineation of the Wilms tumour ROIs, visual
inspection showed that 8/37 (21.6%) had a substantial mis-
match between the radiologists; these were re-defined after
consensus. The remaining 29Wilms tumours had a high level
of agreement between radiologists with an average overlap-
ping area of 88% (SD, 0.67). After adjustment of the 8 mis-
matched ROIs, there was high similarity in the size of the 37
Wilms tumours as defined by the two readers, with an ICC of
0.98 (ICC prior to adjustment, 0.96). There also was high
similarity in the size of the necrotic ROIs defined by the two
readers, with an ICC of 0.83.
Analysis
All multiple linear regressionmodels used to predict fractional
enhancement were statistically significant (p < 0.05), as
shown in Table 1.
The combination of D from IVIM and T1wnorm gave the
strongest regression model F(2, 34) = 13.78, p < 0.001, adjusted
R2 = 0.42. However, this represented only a very marginal im-
provement compared to ADC (F(2, 34) = 13.2, p < 0.001, ad-
justed R2 = 0.40). While the other three models all reached sig-
nificance (p < 0.05); the higher p values and comparatively low
adjustedR2 values indicated that they did not describe the data as
well. Due to the similarity in performance between the regres-
sion models based on D (IVIM) and ADC (mono-exponential),
and the fact that ADC data are more widely acquired clinically,
we chose to focus on the ADC-based model for further analysis.
Figure 2 demonstrates the relationship between both ADC
and T1wnorm vs. fractional enhancement. Both ADC
(p < 0.001) and T1wnorm (p = 0.001) added significantly to
the prediction, with both increased ADC and increased
T1wnorm being associated with reduced fractional enhance-
ment. The standard error of the estimate was 0.24.
Using the ADC-T1wnorm model, predicted enhancement
was calculated according to the regression model given by
Eq. 3, derived the ‘fitlm’ algorithm in Matlab:
Predicted enhancement ¼ 1:85 – 408:4  ADCð Þ – 0:4  T1wnormð Þ ð3Þ
where ADC is measured in mm/s2.
Fig. 1 Flowchart of study
population showing exclusion
criteria. DWI, diffusion-weighted
imaging; T1w, T1 weighted
imaging; np, number of patients;
nt, number of tumours
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Comparisons between fractional enhancement and predict-
ed enhancement maps in three representative patients are il-
lustrated in Fig. 3. Both highlight similar regions of enhancing
and non-enhancing tissues.
The level of agreement between fractional enhancement
and predicted enhancement is illustrated in the Bland-
Altman plot in Fig. 4. There was a slight bias (9%) in predicted
values overestimating the level of enhancement across a wide
range of enhancement levels (mean difference = − 0.093, 95%
CI = [− 0.52, 0.34]).
ROC analysis provided an optimal threshold to distinguish
between viable and necrotic tissue, based on fractional en-
hancement (Fig. 5a). The upper threshold was 0.33 (i.e. voxels
showing less than 33% signal enhancement on T1w imaging,
after administration of gadolinium, were classified as necrot-
ic). This threshold provided a sensitivity of 85% and specific-
ity of 90% for identifying the ‘gold-standard’ necrotic tissue,
with an AUC of 0.93.
Figure 5b displays a box and whisker plot of the fractional
enhancement values in the manually defined necrotic and vi-
able ROIs across the entire cohort. An independent sample
T test revealed a significant difference between fractional en-
hancement values in the viable (mean, 0.73; SD, 0.33) and
necrotic (mean, 0.14; SD, 0.2) voxels, t(195364) = − 446.96,
p < 0.001. The optimum threshold (0.33) which separates ne-
crotic and viable tumour tissue is also highlighted in Fig. 5b.
Discussion
This study investigated whether necrosis (non-enhancing
tissue) could be identified without using gadolinium
contrast-enhanced T1w images in Wilms tumour. We found
good agreement between mean tumour enhancement values
calculated using non-gadolinium-based metrics (ADC and
T1wnorm) and the level of enhancement measured using gad-
olinium in the same tumours. Additionally, a threshold of
maximum enhancement in necrotic tissue was determined,
which separated viable and necrotic tissue in good agreement
with manually delineated necrotic tumour regions, as defined
by two specialist paediatric radiologists. As such, this thresh-
old could be used to quantify the total fraction of necrotic
tissue in Wilms tumours in future studies, using either mea-
sured or predicted enhancement values.
Necrosis withinWilms tumours can indicate chemotherapy
response, with high volumes of necrosis representative of
‘good response’ [13]. Quantifying the percentage of necrosis
in Wilms tumour has previously been challenging as histolog-
ical methods usually only sample a sub-section of tissue.
Thus, measuring the level of necrosis of the entire tumour
volume using imaging-based assessment without exogenous
contrast is greatly beneficial. Additionally, in instances of bi-
lateral Wilms tumour, whole tumour resection is not possible
and thus necrosis fractions cannot be quantified using
Fig. 2 a Linear regression of
mean ADC (apparent diffusion
coefficient) versus mean
fractional enhancement in 37
Wilms tumours, adjusted R2 =
0.19. b Linear regression of mean
T1wnorm (normalised quantitative
T1-weighted imaging) versus
mean fractional enhancement in
37 Wilms tumours, adjusted R2 =
0.16. For the multiple linear
regression model (with both ADC
and T1wnorm as predictors), the
adjusted R2 was 0.40 (p < 0.001)
Table 1 The p values, R2, and
correlation coefficients (β) of the
five multiple regression models
used to predict fractional
enhancement, based on a
combination of T1wnorm and one
of the diffusion parameters. ADC,
D, and D* were all measured in
standard units of mm/s2. f and
T1wnorm are unitless
Diffusion parameter β0 (intercept) β1 (diffusion) β2 (T1wnorm) Model p value Model adjusted R
2
ADC 1.85 − 408.4 − 0.4 5.7 × 10−5 0.40
D (IVIM) 1.83 − 419.64 − 0.4 4.2 × 10−5 0.42
D* (IVIM) 1.18 − 1.09 − 0.3 0.017 0.17
f (IVIM) 1.01 1.07 − 0.34 0.025 0.15
f × D*(IVIM) 1.2 − 5.53 − 0.33 0.023 0.15
Mono-exponential fitted parameters: ADC, apparent diffusion coefficient. Bi-exponential (IVIM) fitted parame-
ters: D, thermally-driven, ‘slow’ diffusion; D*, flow-driven, ‘fast’ diffusion; f, volume fraction associated with
‘fast’ diffusion
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Fig. 3 Examples of single axial
slices from three representative
Wilms tumours. a, c, e Fractional
enhancement maps of the Wilms
tumours (outlined in red),
measured using gadolinium. b, d,
f The same slices of the same
Wilms tumours from predicted
enhancement maps, predicted
using Eq. 3 (without gadolinium).
Increased signal represents
greater enhancement, and hence
more viable tissue. Tumour
details: A and B—subtype,
mixed; age at scan, 11 years. C
and D—subtype, blastemal; age
at scan, 1.8 years. E and F—
subtype, mixed; age at scan,
1.08 years
Fig. 4 The Bland-Altman plot
showing the level of agreement in
mean enhancement values in 37
Wilms tumours, as calculated
using fractional enhancement
(FE) and predicted enhancement
(PE) from the ADC-T1wnorm
model (Eq. 3)
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histological analysis. Furthermore, DWI and T1w imaging are
routinely acquired in Wilms tumour patients, so no additional
scan time is needed, aiding the transference to clinical
practice.
The current gadolinium-based method of identifying non-
enhancing tissue has some possible limitations due to poten-
tial adverse reactions in patients (including nausea, headaches,
and irritation), and the as-yet-unknown impact of the accumu-
lation of contrast agent in patients undergoing repeated
follow-up imaging [4]. Additionally, gadolinium may not al-
ways be appropriate in Wilms tumour, for example if the pa-
tient has renal failure, which will be dependent on co-morbid
disorders, tumour staging, treatment timeline, and whether the
tumour is bilateral [14, 15]. Additionally, chemotherapy drugs
can lead to nephrotoxicity [16]. For these reasons, alternative
approaches for predicting enhancement and identifying and
quantifying necrotic tissue without gadolinium is potentially
beneficial.
ADC is a well-defined diffusion parameter; however, mul-
tiple b value DWI data allows non-Gaussian diffusion models
to be applied, which provide additional fitted parameters. For
example, D and f have shown higher accuracy in
distinguishing between enhancing and non-enhancing kidney
lesions compared to ADC [17]. Furthermore, bi-exponential
models have been suggested rather than mono-exponential for
more reliable diffusion estimates of healthy kidney tissue [18].
This study compared ADC and IVIM parameters in predicting
fractional enhancement. Interestingly, f and f × D* regression
models did not reach high significance. f represents the con-
tribution to the DWI signal due to blood flowing in the ran-
domly orientated capillary network [9], and f × D* represents
a surrogate measure of blood flow [19]. Due to the lack of
blood flow in necrotic tissue, it would be expected that these
parameters would be better predictors of fractional enhance-
ment; however, our results suggest this is not the case. This
may be because it is beyond the sensitivity of the IVIMmodel
to identify the small level of perfusion in viable Wilms tu-
mours compared to non-enhancing tissue.
D produced the strongest regression model; however, the
difference between the predictive power of D and ADC was
minimal. Due to the similarity in the performance of these two
predictors and the fact that ADC values are routinely acquired
in clinical practice (whereas D requires longer, multiple
b value acquisitions), ADC represents the preferred option for
predicting fractional enhancement when combined with
T1wnorm. This combination is needed as ADC alone cannot
account for necrosis via coagulation, and as can be seen
(Fig. 2), the regression is much stronger when T1wnorm is
added as a predictor.
The study had several limitations. Firstly, slightly different
b values were used for a small number of our patients; how-
ever, previous work has shown high reproducibility between
ADC values acquired on different scanners with varying
b values [20]; thus, this is unlikely to influence our analysis.
Secondly, when comparing the measured and predicted mean
enhancement values, the predicted values were slightly
overestimated. However, this bias was small (9%) and may
be due to registration errors between T1w and ADC maps.
Thirdly, our sample size was fairly small, and a more robust
model may be possible with a larger cohort. Furthermore, we
did not assess tumour necrosis independently using histolog-
ical methods. However, it is important to note that for histo-
logical analysis of Wilms tumour, only a sub-section of the
tumour is sampled, and this may not accurately reflect the total
necrosis volume. As such, we preferred in this study to use
visual assessment of the entire tumour volume, using all clin-
ically availableMRI scans, to ensure the entire tumour volume
was assessed.
An additional limitation may arise from the possible
reliance of our model on the specifics of the T1w protocol
Fig. 5 a Receiver operator characteristics to determine a threshold which
best separates necrotic and viable Wilms tumour tissue. The optimum
upper threshold (0.33), whereby voxels displaying enhancement above
this value are classified as viable, is highlighted in red. For this threshold,
the area under the curve was 0.93, sensitivity was 85%, and the specificity
was 90%. b Box and whisker plot displaying fractional enhancement of
every voxel from the 37 Wilms tumours which were either classified as
necrotic or viable. The dotted line reflects the optimum threshold (0.33
fractional enhancement) for this separation based on ROC analysis which
is shown in (a)
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used in this study. Alterations in the delay time between
gadolinium administration and T1w imaging may lead to
different levels of enhancement on contrast-enhanced T1w
scans. However, as our model uses the fractional differ-
ence between the pre- and post-contrast T1w signal, pro-
vided the T1w protocol remains consistent between these
two acquisitions, the influence of variations in the spe-
cifics of the T1w acquisition between different institutions
should mostly cancel out.
Finally, gadolinium is frequently administered for indi-
cations broader than necrosis assessment, for example vas-
cular anatomy, and detecting lesions in a variety of organs.
We acknowledge that the proposed method cannot entirely
replace gadolinium. Despite this, our method would be a
suitable alternative for those with severe renal impairment
and limit the cumulative gadolinium exposure for patients
who have repeated follow-up MRI scans. Gadolinium-free
MRI examinations are currently being investigated for pae-
diatric oncology [21], and the proposed model could facil-
itate this, given that it uses data acquired as part of the
clinical standard.
In conclusion, the proposedmodel predicts enhancement in
Wilms tumour without gadolinium and provides a visual rep-
resentation of tissue viability and necrosis within tumours. A
threshold of maximum enhancement in necrotic regions has
also been generated, allowing the percentage of necrotic tissue
to be quantified in future Wilms tumour studies, using
imaging-based methods.
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